GlassScriptPhysician profile
Manuel Castro-Borobio
NPI 1164788022
$7,539.17
in general payments reported to CMS, 2019-2025
40 companies · $818 in 2025
The $818 reported for 2025 was more than what 76% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,096 · 2020: $1,371 · 2021: $3,520 · 2022: $146 · 2023: $121 · 2024: $466 · 2025: $818.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,405.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,405.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cipla USA INC. | $1,263.80 | 2021 | |
| Viiv Healthcare Company | $827.28 | 2019-2025 | Cabenuva, Dovato, Apretude |
| Gilead Sciences, INC. | $749.41 | 2019-2025 | Biktarvy |
| Octapharma USA, INC. | $604.25 | 2020-2021 | |
| Paratek Pharmaceuticals, INC. | $534.58 | 2019-2025 | Nuzyra |
| Merck Sharp & Dohme LLC | $467.06 | 2019-2025 | Pifeltro, Zerbaxa, Delstrigo |
| Insmed, INC. | $311.67 | 2019-2025 | Arikayce, Brinsupri |
| Abbvie INC. | $297.19 | 2019-2025 | |
| Melinta Therapeutics, LLC | $294.52 | 2019-2024 | Rezzayo, Orbactiv, Kimyrsa |
| Amgen INC. | $221.28 | 2019-2021 | |
| Allergan, INC. | $221.22 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $168.20 | 2019-2021 | |
| La Jolla Pharmaceutical Company | $166.37 | 2021-2025 | Zevtera |
| Takeda Pharmaceuticals U.S.A., INC. | $146.69 | 2020-2025 | Cuvitru |
| Janssen Biotech, INC. | $135.31 | 2019-2021 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $130.28 | 2020-2022 | |
| Mayne Pharma Commercial LLC | $103.69 | 2020-2021 | |
| Pfizer INC. | $90.48 | 2019-2025 | |
| Tetraphase Pharmaceuticals, INC. | $87.11 | 2019-2020 | |
| Napo Pharmaceuticals INC | $77.01 | 2019-2025 | Mytesi |
| Grifols USA, LLC | $62.58 | 2020-2021 | |
| Csl Behring | $54.67 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $52.74 | 2020-2021 | |
| Nabriva Therapeutics, Plc | $48.65 | 2020-2021 | |
| Invivyd INC | $48.26 | 2025 | Pemgarda |
| Smith+Nephew, INC. | $44.10 | 2021 | |
| Shionogi INC | $40.13 | 2021-2025 | Fetroja |
| Theratechnologies INC. | $38.93 | 2019-2025 | Egrifta, Trogarzo |
| Astellas Pharma US INC | $36.56 | 2019 | |
| Mylan Institutional INC. | $26.47 | 2019 | |
| Horizon Therapeutics Plc | $22.87 | 2021 | |
| Kedrion Biopharma INC. | $21.52 | 2019 | |
| Organogenesis INC. | $20.90 | 2025 | Affinity |
| Kerecis Limited | $20.62 | 2019 | |
| Tersera Therapeutics LLC | $20.46 | 2024 | Quzyttir |
| Tg Therapeutics, INC. | $19.35 | 2023 | |
| Ferring Pharmaceuticals INC. | $19.00 | 2025 | Rebyota |
| Surgenex LLC | $18.18 | 2025 | Pellograft, Surmatrix, Ardeograft |
| Novartis Pharmaceuticals Corporation | $14.03 | 2021 | |
| Ets Wound Care LLC | $11.75 | 2025 | Mirragen Advanced Wound Matrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manuel Castro-Borobio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.